Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orhan Sezer

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
Clinical & Developmental Immunology|December 23, 2011
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantationSebastian Kobold, Sinje Tams, Tim Luetkens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myelomaJesús F San-Miguel, Paul G Richardson, Andreas Günther, et al.
Journal of the National Cancer Institute|June 30, 2012
Role of interleukin 16 in multiple myelomaDjordje Atanackovic, York Hildebrandt, Julia Templin, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2009
Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastasesKristin Harris, Edward Chow, Liying Zhang, et al.
British Journal of Haematology|July 7, 2007
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaMartin Kropff, Guido Bisping, Elke Schuck, et al.
Annals of Hematology|September 19, 2003
Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 studyAndreas Engert, Volker Diehl, Jeremy Franklin, et al.
Leukemia & Lymphoma|June 1, 2010
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approachesMonika Engelhardt, Martina Kleber, Josefina Udi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22Edward Chow, Amanda Hird, Galina Velikova, et al.
Haematologica|March 25, 2014
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma NetworkNiels W C J van de Donk, Antonio Palumbo, Hans Erik Johnsen, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Clinical & Developmental Immunology|December 23, 2011
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantationSebastian Kobold, Sinje Tams, Tim Luetkens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myelomaJesús F San-Miguel, Paul G Richardson, Andreas Günther, et al.
Journal of the National Cancer Institute|June 30, 2012
Role of interleukin 16 in multiple myelomaDjordje Atanackovic, York Hildebrandt, Julia Templin, et al.
European Journal of Cancer (Oxford, England : 1990)|July 29, 2009
Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastasesKristin Harris, Edward Chow, Liying Zhang, et al.
British Journal of Haematology|July 7, 2007
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaMartin Kropff, Guido Bisping, Elke Schuck, et al.
Annals of Hematology|September 19, 2003
Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)Angelika Böhme, Markus Ruhnke, Dieter Buchheidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 studyAndreas Engert, Volker Diehl, Jeremy Franklin, et al.
Leukemia & Lymphoma|June 1, 2010
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approachesMonika Engelhardt, Martina Kleber, Josefina Udi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 23, 2008
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22Edward Chow, Amanda Hird, Galina Velikova, et al.
Haematologica|March 25, 2014
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma NetworkNiels W C J van de Donk, Antonio Palumbo, Hans Erik Johnsen, et al.
Pageof 11